Targeted Medical Pharma to Present at 2013 Aegis Capital Healthcare Conference

Los Angeles, CA, September 24th, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced that the company’s CEO and Chief Science Officer William Shell, M.D. along with President and Chief Operating Officer, David Silver M.D., will be presenting at the Aegis Capital 2013 Healthcare Conference being held at The Encore at Wynn Hotel in Las Vegas, Nevada on Friday, September 27, 2013 at 11:30 a.m. in Room 1.

The conference will feature more than 45 healthcare companies from around the world and will feature presentations from industry-leading growth companies in the healthcare sector. Following corporate presentations, executives will have the opportunity to participate in question-and-answer sessions with fund managers, institutional and private investors, industry analysts, and Aegis Capital’s top-performing brokers

According to a recent research report by Falls Church, VA-based Technology Catalysts International, the global medical foods market is estimated at approximately $12 billion and growing. The report notes that consumer and scientific interest in the relationship between diet, health, and alternative medicines has created an increased demand for medical foods.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders.  The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I. Targeted Medical Pharma also is engaged in the development of a proprietary line of dietary supplements.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # #